Denmark-based BioInnovation Institute (BII) is expanding its European CardioMetabolic Bridge to Munich and Berlin. Backed by up to DKK 450 million (around €60 million) from the Novo Nordisk Foundation, the initiative aims to accelerate the translation of academic research into metabolic and cardiovascular diseases into drug development and biotech companies. Following the establishment of an innovation hub in London, the two German locations are its next European sites. Laboratory infrastructure is planned, but details will not be finalized for several months.
